Cannabis Law Report

JUNE 21, 2021

June 14, 2021 – June 18, 2021. OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. PsyIndex Weekly Update. ATAI Life Sciences N.V. Market Performance. (OTC:

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. The analogy would be this. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

SEPTEMBER 18, 2020

Conventional forms of treatment are often accompanied by adverse side effects but there is hope for effective treatment with fewer side effects. . million of NWS Health funding for their Cannabinoid Therapeutics and Brain and Mind Centre to see if cannabidiol can be that effective treatment for spinal cord injury.

Treatment 98

Treatment Chronic Pain Research and Development CBD 98

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. The Marijuana Regulatory Agency issued a request for proposals for the 2021 Veteran Marijuana Research Grant Program on Tuesday, June 1. Read more at.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

TheAnswerPage

JUNE 19, 2021

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

Cannabis Law Report

AUGUST 26, 2022

CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. Apart from this, various clinical trials are done for multiple conditions. billion in 2021. Is CBD an effective treatment for people with seizures and epilepsy? It has been predicted to reach about $47.22

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

TheAnswerPage

NOVEMBER 30, 2021

Psilocybin, the hallucinogen found in “magic mushrooms” has been used in clinical trials. According to the CSA, schedule I substances have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

Clinical Trials 52

Clinical Trials Safety Treatment THC 52

Cannabis Law Report

JUNE 24, 2022

We have covered this but it is interesting to see theat the Guardian have picked up the story… All clinical trials into the psychoactive drug MDMA are being reviewed by Canadian regulators after complaints about abuse of study participants by a trailblazing American psychedelic research organization.

Clinical Trials 52

Clinical Trials Treatment Pharmaceutical Medicine 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Presentations at ASN Kidney Week 2021, November 4-7, 2021.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960). USOTC: USMJ).

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. For instance, as of June 2021, InMed Pharmaceuticals, Inc.,

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

AUGUST 10, 2021

As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021. With these injustices, and many more, it is clear why many BIPOC might be disinterested in participating in such studies today.

Clinical Trials 105

Clinical Trials Research and Development Therapy Treatment 105

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. RADNOR, Pa.–(BUSINESS Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021. On 5 August 2021, the TGA announced that an Independent Expert Panel had been established to undertake the review. The review excludes pre-clinical trials (i.e.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Veriheal

MARCH 20, 2023

Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Connecticut Gov. Minnesota Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

JUNE 23, 2021

NEO: AWKN) began trading today, June 23, 2021, on the NEO Exchange Inc. The company has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021 (Bristol, London, and Manchester). David Nutt), starts in Q4 2021.

Clinical Trials 110

Clinical Trials Therapy Research and Development Treatment 110

Cannabis Law Report

SEPTEMBER 6, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. during 2021-2026. Cannabis is safer and has less severe side effects in comparison to other treatment options.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Canna Law Blog

NOVEMBER 15, 2021

There was a fascinating panel on the use of ketamine treatments for, among other things, depression and anxiety disorders. We continue to see an uptick in ketamine clinic transactions (the complexities of which we have written about extensively ). Pharmaceutical start-ups are betting on the treatment potential of psychedelics.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million for the three months ended September 30, 2021, from approximately $1.48

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? 17 Aug 2021. Fletcher S. Child: care, health and development.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

TheAnswerPage

MAY 29, 2021

Is haloperidol more effective than odansetron for the treatment of the nausea and vomiting associated with cannabinoid hyperemesis syndrome? According to the results of a randomized controlled trial involving 33 patients with cannabinoid hyperemesis syndrome, haloperidol (0.05 mg/kg or 0.1 Ruberto, A., Sivilotti, M., Forrester, S.,

Clinical Trials 52

Clinical Trials Cannabinoids Treatment Recreational 52

Cannabis Law Report

AUGUST 13, 2021

Derived from Salvia divinorum, SalA is a unique non-nitrogenous agonist of the kappa-opioid receptor (KOR) with potential use in treatment-resistant depression (TRD), substance use disorder (SUD) and pain. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Veriheal

JULY 24, 2023

The study’s results blew researchers away showing that psilocybin’s effect on those with depression “…was about four times larger than what clinical trials have shown for traditional antidepressants on the market”. Jada Pinkett-Smith said she was introduced to psilocybin about a decade ago on a 2021 episode of her show, Red Table Talk.

Therapy 98

Therapy Clinical Trials Treatment Cannabis 98

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. The new patent, US Patent … London, UK – 23 November 2021.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Veriheal

MAY 25, 2023

This powerful anesthetic may offer swift symptomatic relief from the symptoms of widespread mental health conditions, including anxiety, bipolar disorder, treatment-resistant depression /major depression, PTSD (post- traumatic stress disorder), OCD ( obsessive-compulsive disorder), and various addictions/substance use disorders.

Medicine 98

Medicine Blood Pressure Therapy Clinical Trials 98

Cannabis Law Report

MAY 28, 2022

We lateraled to Husch Blackwell together in April 2021 as part of a larger team. We have been following the research and development of these medicines for psychiatric conditions such as PTSD and treatment-resistant depression. How did this come to fruition? Read full article at.

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. Vigorous scientific research and clinical trials are needed.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JANUARY 11, 2022

The new distributor in the Australian medicinal cannabis industry – The Entourage Effect – has signed a firstof its kind deal with innovative medical cannabis clinic MiDispensary. MiDispensary burst onto the scenes in August 2021, offering Australians high quality treatment at an affordable yearly fee.

Access 52

Access Patients Clinical Trials Legalization 52